Endo Axiom
A first‑in‑class oral insulin platform using liver‑targeting nanotechnology, addressing a multi‑billion‑dollar diabetes market with no currently approved oral product.
How the company was formed, and what it is building.
Endo Axiom is focused on the prevention of autoimmune diseases and improving the quality of life of diabetics. The lead programme — EA‑100 — is an oral insulin therapy delivered via liver‑targeting nanotechnology, addressing a multi‑billion‑dollar diabetes market with no currently approved oral product.
The science was developed over more than a decade at the ANZAC Research Institute in Concord, NSW, by Professor Victoria Cogger, Professor David Le Couteur AO and Dr Nicholas Hunt. Proto Axiom partnered with the inventors in April 2023 to form the company, license the underlying IP from the University of Sydney, install management, and fund the preclinical programme.
EA‑100 is on track for first‑in‑human Phase I clinical entry in 2026, approximately three years from company formation.
- Founded
- 2023
- Origin
- University of Sydney / ANZAC Research Institute
- Sector
- Therapeutics
- Modality
- Oral insulin · Nanotechnology
Founders and key team.
Where the programme is now, and what comes next.
- Now
- IND‑enabling preclinical studies for EA‑100. CMC scale‑up active.